BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 29422324)

  • 1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
    Fernández-Díaz C; Loricera J; Castañeda S; López-Mejías R; Ojeda-García C; Olivé A; Rodríguez-Muguruza S; Carreira PE; Pérez-Sandoval T; Retuerto M; Cervantes-Pérez EC; Flores-Robles BJ; Hernández-Cruz B; Urruticoechea A; Maíz-Alonso O; Arboleya L; Bonilla G; Hernández-Rodríguez Í; Palma D; Delgado C; Expósito-Molinero R; Ruibal-Escribano A; Álvarez-Rodríguez B; Blanco-Madrigal J; Bernal JA; Vela-Casasempere P; Rodríguez-Gómez M; Fito C; Ortiz-Sanjuán F; Narváez J; Moreno M; López-Corbeto M; Mena-Vázquez N; Aguilera-Cros C; Romero-Yuste S; Ordóñez S; Villa-Blanco I; Gonzélez-Vela MC; Mora-Cuesta V; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2018 Aug; 48(1):22-27. PubMed ID: 29422324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
    Fernández-Díaz C; Castañeda S; Melero-González RB; Ortiz-Sanjuán F; Juan-Mas A; Carrasco-Cubero C; Casafont-Solé I; Olivé A; Rodríguez-Muguruza S; Almodóvar-González R; Castellanos-Moreira R; Rodríguez-García SC; Aguilera-Cros C; Villa I; Ordóñez-Palau S; Raya-Alvarez E; Morales-Garrido P; Ojeda-García C; Moreno-Ramos MJ; Bonilla Hernán MG; Hernández Rodríguez I; López-Corbeto M; Andreu JL; Jiménez de Aberásturi JRD; Ruibal-Escribano A; Expósito-Molinero R; Pérez-Sandoval T; López-Robles AM; Carreira-Delgado P; Mena-Vázquez N; Urruticoechea-Arana A; Peralta-Ginés C; Arboleya-Rodríguez L; Narváez García FJ; Palma-Sánchez D; Cervantes Pérez EC; Maiz-Alonso O; Alvarez-Rivas MN; Fernández-Melón J; Vela Casasempere P; Cabezas-Rodríguez I; Castellvi-Barranco I; González-Montagut C; Blanco-Madrigal J; Del Val-Del Amo N; Fito MC; Rodríguez-Gómez M; Salgado-Pérez E; García-Magallón B; Hidalgo-Calleja C; López-Sánchez R; Fernández-Aguado S; Fernández-López JC; Castro-Oreiro S; Serrano-García I; García-Valle A; Romero-Yuste S; Expósito-Pérez L; Pérez-Albadalejo L; García-Aparicio A; Quillis-Marti N; Bernal-Vidal JA; Loricera-García J; Hernández JL; González-Gay MA; Blanco R
    Rheumatology (Oxford); 2020 Dec; 59(12):3906-3916. PubMed ID: 33068439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
    Fernández-Díaz C; Atienza-Mateo B; Castañeda S; Melero-Gonzalez RB; Ortiz-SanJuan F; Loricera J; Casafont-Solé I; Rodríguez-García S; Aguilera-Cros C; Villa-Blanco I; Raya-Alvarez E; Ojeda-García C; Bonilla G; López-Robles A; Arboleya L; Narváez J; Cervantes E; Maiz O; Alvarez-Rivas MN; Cabezas I; Salgado E; Hidalgo-Calleja C; Fernández S; Fernández JC; Ferraz-Amaro I; González-Gay MA; Blanco R;
    Rheumatology (Oxford); 2021 Dec; 61(1):299-308. PubMed ID: 33779697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
    Tardella M; Di Carlo M; Carotti M; Giovagnoni A; Salaffi F
    Clin Rheumatol; 2021 Dec; 40(12):4861-4867. PubMed ID: 34313866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.
    Tardella M; Di Carlo M; Carotti M; Ceccarelli L; Giovagnoni A; Salaffi F
    Inflammopharmacology; 2022 Jun; 30(3):705-712. PubMed ID: 35462572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
    Vicente-Rabaneda EF; Atienza-Mateo B; Blanco R; Cavagna L; Ancochea J; Castañeda S; González-Gay MÁ
    Autoimmun Rev; 2021 Jun; 20(6):102830. PubMed ID: 33887489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
    Atienza-Mateo B; Fernández-Díaz C; Vicente-Rabaneda EF; Melero-González RB; Ortiz-Sanjuán F; Casafont-Solé I; Rodríguez-García SC; Ferraz-Amaro I; Castañeda S; Blanco R;
    Eur J Intern Med; 2024 Jan; 119():118-124. PubMed ID: 37673775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
    Mochizuki T; Ikari K; Yano K; Sato M; Okazaki K
    Mod Rheumatol; 2019 May; 29(3):413-417. PubMed ID: 29798700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
    Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
    Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
    Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
    JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.
    Mena-Vázquez N; Godoy-Navarrete FJ; Manrique-Arija S; Aguilar-Hurtado MC; Romero-Barco CM; Ureña-Garnica I; Espildora F; Añón-Oñate I; Pérez-Albaladejo L; Gomez-Cano C; Jimenez-Núñez FG; Padin-Martín MI; Fernández-Nebro A
    Clin Rheumatol; 2021 Jan; 40(1):133-142. PubMed ID: 32557255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
    Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
    Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
    Roubille C; Haraoui B
    Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study.
    Cassone G; Manfredi A; Atzeni F; Venerito V; Vacchi C; Picerno V; Furini F; Erre GL; Tomietto P; Fedele AL; Della Casa G; Nucera V; Giannitti C; Salvarani C; Sebastiani M
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.
    Akiyama M; Kaneko Y
    Autoimmun Rev; 2022 May; 21(5):103056. PubMed ID: 35121155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment.
    Rojas-Serrano J; González-Velásquez E; Mejía M; Sánchez-Rodríguez A; Carrillo G
    Reumatol Clin; 2012; 8(2):68-71. PubMed ID: 22341526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
    Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
    Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
    Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
    Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.